top of page

ENHERTU - Discover a new indication & how it may help certain patients with unmet needs ~ March 4th


Indication

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.









 
 
 

Comments


BONS logo.png

Contact:

Daunielle Ricardi, President

Alissa Gentile, Treasurer

Cameron Keith, Social Media Coordinator

Email: BonsSocialMedia@gmail.com

  • Facebook
  • Instagram
  • LinkedIn
Earthen Media-4.png
bottom of page